Calcium 2-amino ethyl phosphoric acid

  Calcium 2-amino ethyl phosphoric acid (Ca-AEP or Ca-2AEP) is a vital component in the structure of cell membranes in the human body. It was discovered by the eminent biochemist Erwin Chargaff in 1941. Ca-AEP has been shown to help maintain cell membrane integrity and improve cellular functions. It was patented by Dr. Hans Alfred Nieper and Franz Kohler

Additional recommended knowledge

How to ensure accurate weighing results every day?

Better weighing performance in 6 easy steps

Daily Sensitivity Test

This article describes the history of Calcium 2-Amino Ethyl Phosphoric Acid treatment, current uses, and risks

Terminology and glossary

Calcium 2-amino ethyl phosphoric acid (Ca-AEP or Ca-2AEP) is also called calcium ethylamino-phosphate (calcium EAP), Calcium Colamine Phosphate, Calcium 2-Aminoethyl Esther of Phosphoric Acid, and Calcium 2-Amino Ethanol Phosphate

2-AEP (2-amino ethyl phosphoric acid) the salt of the amino acid Arginine and Orotic acid, is a substance which plays a role as a component in the cell membrane and at the same time has the property to form a complex with minerals. This mineral transporter goes into the outer layer of the outer cell membrane where it releases its associated mineral and is itself metabolized with the structure of the cell membrane. [Unclear] The effect here is an increase of the electrical condenser function of cell membranes to resist toxins and viruses which may otherwise enter the cell and cause cellular degeneration. [Citation needed] Calcium 2-AEP is said to be effective for repairing cell membrane damage. [Citation needed] In Germany, calcium, potassium and magnesium 2-AEP are officially declared as the only active substances for the treatment of multiple sclerosis. [Citation needed]

History, Treatments, Uses, and Risks

CA-2AEP was discovered by Erwin Chargaff, best known for his work that eventually lead to the discovery of the double helix structure of DNA, in 1941. His findings were largely ignore for the first two decades but studies over the last 30 years have shown that Ca-AEP plays a vital role in maintaining cell membrane integrity and improving cellular functions. [Citation needed] People have been using this to treat a host of ailments including multiple sclerosis, diabetes, asthma and immune disorders.

The first trial applications of Ca-AEP were for the treatment of multiple sclerosis (MS). [Citation needed] In 1967 the German Health Authority approved the use of Ca-AEP for MS. MS, an inflammatory demyelinating condition, is one of the most common diseases of the central nervous system (brain and spinal cord). Myelin, the fatty material that surrounds nerves, acts as an insulator, much like the covering of an electric wire. An analysis of more than 2,000 patients who were treated with colamine salts in Germany over the course of 24 years revealed greater efficacy from Ca-AEP treatments than other known treatments. [Citation needed] In 1986, Dr. George Morrissette conducted a retrospective poll of patients in the USA who originally had begun Ca-AEP treatment in Germany for MS. 82% of the almost 300 patients that entered the study showed a positive benefit from Ca-AEP therapy. And when treatment began in the early stages of MS, positive results rose to 92%. [Citation needed]

After 30 years of Ca-AEP and Calcium Orotate therapies with over 3,500 patients with multiple sclerosis, the risk of bone fractures was drastically reduced. [Citation needed]] Furthermore, surgeons in six surgical centers located in USA and Europe reported finding extremely solid bone when implanting new joints in patients who were taking Ca-AEP combined with calcium and magnesium Orotate for at least four years prior to their surgeries. [Citation needed]

In 1967 the German Health Authority (FDA equivalent) approved Calcium 2-AEP as an official treatment for Multiple Sclerosis. In fact, 2-AEP is the only natural Official MS treatment reimbursed by the German equivalent of the US Social Security System. [Citation needed]

The U.S. National Multiple Sclerosis Society states that “calcium EAP protocol is not recommended by the Medical Advisory Board of the National MS Society.” The National MS Society warns of side effects and risk, but they do not list any on their website for this treatment. They do state that it “may include a powerful drug that suppresses the immune system” but they do not mention what this drug is. [This statement appears to be out of context]

Calcium 2-AEP is actually manufactured by numerous nutraceutical companies and is sold online and in health food stores.

References

• Ward Dean, M.D. and Jim English (June 1999) Membrane Integrity Factor Aids Treatment of Multiple Sclerosis, Asthma and Osteoporosis

http://www.medaus.com/index.php?view=43&p=73

• Hans Nieper, M.D. (1992) Let’s Live Magazine “Mineral Transporters”

Reproduced by the Brewer Science Library with permission from Let's Live magazine http://www.mwt.net/~drbrewer/mintrans.htm

• National MS Society (Feb 2006) The MS Information SourceBook

http://www.nationalmssociety.org/Sourcebook-Calcium%20EAP.asp